Anaphylaxis

Our political system ensures that everyone throughout the country has representation, Melinda M. Rathkopf, MD, MBA, told Healio. Leveraging that representation is essential when physicians need to advocate for their patients and themselves.

Advocates were pleased to learn about the FDA’s approval of ARS Pharmaceuticals’ neffy epinephrine nasal spray, which may have a significant impact on the safety and quality of life of families with allergy.

SAN ANTONIO — Preparation is key to successful oral food challenges, said Maria Crain, APRN, CPNP-PC, AE-C, pediatric nurse practitioner, University of Texas Southwestern Medical Center Food Allergy Center.

Healio has compiled July’s most-read news in asthma and allergy.

The FDA has approved Palforzia for children aged 1 to 3 years who have a peanut allergy that has been diagnosed by a physician, according to a press release from its manufacturer, Stallergenes Greer.

A recent study found that health care professionals were increasingly able to identify infants and young children with anaphylaxis by following modified criteria.

A crossover study revealed that dry powder epinephrine administered via nasal spray yielded drug exposures equal to or higher than those provided by autoinjectors in a canine model.

Modified criteria that incorporated symptoms specific to infants and young children increased identification of anaphylaxis in these age groups, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended marketing authorization of ARS Pharmaceuticals’ EURneffy epinephrine nasal spray in the European Union, according to a press release.

New guidance was established for clinicians in the U.K. in order to implement the use of Palforzia in oral immunotherapy for patients with a peanut allergy, according to a study published in Clinical & Experimental Allergy.